Nursing

Coronavirus

2019-20 coronavirus outbreak

Biology

Virology

Clinical trial

Neuraminidase

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Outbreak

Drug

Docking (animal)

Drug discovery

Coronavirus disease 2019 (COVID-19)

Bioinformatics

Drug development

Infectious disease (medical specialty)

Pharmacology

Drug repositioning

Medicine

Virus

Pandemic

Disease

Pathology

Clinical Epidemiology and Global Health

No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.

Antivirals for COVID-19: A critical review